{"id":48348,"date":"2025-11-16T00:05:20","date_gmt":"2025-11-15T16:05:20","guid":{"rendered":"https:\/\/flcube.com\/?p=48348"},"modified":"2025-11-16T00:05:21","modified_gmt":"2025-11-15T16:05:21","slug":"brightgene-secures-nmpa-nod-for-bgm1812-obesity-trial-fda-grants-trial-clearance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48348","title":{"rendered":"BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>BrightGene Bio-Medical Techonology Co.,\u202fLtd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688166:SHA\">SHA: 688166<\/a>) disclosed that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has approved the conduct of clinical trials for its <strong>BGM1812<\/strong> long\u2011acting amylin analogue, targeting overweight and obesity. The drug has also received <strong>U.S. Food and Drug Administration (FDA)<\/strong> approval to initiate clinical studies, and the first U.S. patient has already been enrolled.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-overview\">Product Overview<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BGM1812<\/strong> \u2013 a novel, long\u2011acting amylin analogue engineered for superior molecular potency and pharmaceutical stability.<\/li>\n\n\n\n<li><strong>Mechanism of Action<\/strong> \u2013 amylin is a 37\u2011amino\u2011acid satiety peptide co\u2011released with insulin; it suppresses appetite via central satiety pathways, delays gastric emptying, and inhibits glucagon secretion, yielding a multi\u2011pathway weight\u2011loss effect.<\/li>\n\n\n\n<li><strong>Clinical Indication<\/strong> \u2013 overweight or obesity; no other agent with the same target has received global marketing approval for weight\u2011loss.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones\">Regulatory Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Authority<\/th><th>License<\/th><th>Date<\/th><\/tr><\/thead><tbody><tr><td><strong>China<\/strong><\/td><td>NMPA<\/td><td>Clinical\u2011trial approval for BGM1812 (obesity)<\/td><td>14\u202fNov\u202f2025<\/td><\/tr><tr><td><strong>U.S.<\/strong><\/td><td>FDA<\/td><td>Clinical\u2011trial clearance for BGM1812 (weight\u2011loss)<\/td><td>14\u202fNov\u202f2025<\/td><\/tr><tr><td><strong>U.S.<\/strong><\/td><td>\u2013<\/td><td>First patient enrolled in Phase\u202fI trial<\/td><td>24\u202fNov\u202f2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-roadmap\">Clinical Development Roadmap<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fI\/II (China)<\/strong> \u2013 enrollment to begin Q1\u202f2026, focusing on safety, pharmacokinetics, and dosing in adults with BMI\u202f\u2265\u202f25\u202fkg\/m\u00b2.<\/li>\n\n\n\n<li><strong>Phase\u202fI (U.S.)<\/strong> \u2013 early\u2011phase study underway; primary objectives: safety, tolerability, dose\u2011response, and preliminary efficacy in the U.S. obesity population.<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong> \u2013 positive outcomes in both markets could launch a parallel development strategy for later\u2011phase studies and eventual U.S. approval (FDA), followed by international commercialization.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-landscape-amp-opportunity\">Market Landscape &amp; Opportunity<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The global obesity\u2011treatment market is estimated to surpass <strong>$20\u202fB<\/strong> by 2030. BGM1812\u2019s multi\u2011mechanistic approach differentiates it from current single\u2011mechanism therapies such as GLP\u20111 receptor agonists and could enhance adherence due to its once\u2011daily, long\u2011acting profile.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This report includes forward\u2011looking information regarding regulatory approvals, trial enrollment, and commercial prospects. Actual results may differ materially from those expressed herein.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688166_20251114_44ER.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688166_20251114_44ER.\"><\/object><a id=\"wp-block-file--media-a4a038df-5edb-4cd4-b2b5-953b46ffeafc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688166_20251114_44ER.pdf\">688166_20251114_44ER<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/688166_20251114_44ER.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a4a038df-5edb-4cd4-b2b5-953b46ffeafc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BrightGene Bio-Medical Techonology Co.,\u202fLtd. (SHA: 688166) disclosed that China\u2019s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48355,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[2536,62,4361,86,1179],"class_list":["post-48348","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-brightgene-bio-medical-technology","tag-clinical-trial-approval-initiation","tag-hot-targets","tag-obesity","tag-sha-688166"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BrightGene Bio-Medical Techonology Co.,\u202fLtd. (SHA: 688166) disclosed that China\u2019s National Medical Products Administration (NMPA) has approved the conduct of clinical trials for its BGM1812 long\u2011acting amylin analogue, targeting overweight and obesity. The drug has also received U.S. Food and Drug Administration (FDA) approval to initiate clinical studies, and the first U.S. patient has already been enrolled.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48348\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance\" \/>\n<meta property=\"og:description\" content=\"BrightGene Bio-Medical Techonology Co.,\u202fLtd. (SHA: 688166) disclosed that China\u2019s National Medical Products Administration (NMPA) has approved the conduct of clinical trials for its BGM1812 long\u2011acting amylin analogue, targeting overweight and obesity. The drug has also received U.S. Food and Drug Administration (FDA) approval to initiate clinical studies, and the first U.S. patient has already been enrolled.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48348\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-15T16:05:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-15T16:05:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1504.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48348#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48348\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance\",\"datePublished\":\"2025-11-15T16:05:20+00:00\",\"dateModified\":\"2025-11-15T16:05:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48348\"},\"wordCount\":329,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48348#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1504.webp\",\"keywords\":[\"BrightGene Bio-Medical Technology\",\"Clinical trial approval \\\/ initiation\",\"Hot targets\",\"Obesity\",\"SHA: 688166\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48348#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48348\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48348\",\"name\":\"BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48348#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48348#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1504.webp\",\"datePublished\":\"2025-11-15T16:05:20+00:00\",\"dateModified\":\"2025-11-15T16:05:21+00:00\",\"description\":\"BrightGene Bio-Medical Techonology Co.,\u202fLtd. (SHA: 688166) disclosed that China\u2019s National Medical Products Administration (NMPA) has approved the conduct of clinical trials for its BGM1812 long\u2011acting amylin analogue, targeting overweight and obesity. The drug has also received U.S. Food and Drug Administration (FDA) approval to initiate clinical studies, and the first U.S. patient has already been enrolled.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48348#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48348\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48348#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1504.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1504.webp\",\"width\":1080,\"height\":608,\"caption\":\"BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48348#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance - Insight, China&#039;s Pharmaceutical Industry","description":"BrightGene Bio-Medical Techonology Co.,\u202fLtd. (SHA: 688166) disclosed that China\u2019s National Medical Products Administration (NMPA) has approved the conduct of clinical trials for its BGM1812 long\u2011acting amylin analogue, targeting overweight and obesity. The drug has also received U.S. Food and Drug Administration (FDA) approval to initiate clinical studies, and the first U.S. patient has already been enrolled.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48348","og_locale":"en_US","og_type":"article","og_title":"BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance","og_description":"BrightGene Bio-Medical Techonology Co.,\u202fLtd. (SHA: 688166) disclosed that China\u2019s National Medical Products Administration (NMPA) has approved the conduct of clinical trials for its BGM1812 long\u2011acting amylin analogue, targeting overweight and obesity. The drug has also received U.S. Food and Drug Administration (FDA) approval to initiate clinical studies, and the first U.S. patient has already been enrolled.","og_url":"https:\/\/flcube.com\/?p=48348","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-15T16:05:20+00:00","article_modified_time":"2025-11-15T16:05:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1504.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48348#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48348"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance","datePublished":"2025-11-15T16:05:20+00:00","dateModified":"2025-11-15T16:05:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48348"},"wordCount":329,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48348#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1504.webp","keywords":["BrightGene Bio-Medical Technology","Clinical trial approval \/ initiation","Hot targets","Obesity","SHA: 688166"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48348#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48348","url":"https:\/\/flcube.com\/?p=48348","name":"BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48348#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48348#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1504.webp","datePublished":"2025-11-15T16:05:20+00:00","dateModified":"2025-11-15T16:05:21+00:00","description":"BrightGene Bio-Medical Techonology Co.,\u202fLtd. (SHA: 688166) disclosed that China\u2019s National Medical Products Administration (NMPA) has approved the conduct of clinical trials for its BGM1812 long\u2011acting amylin analogue, targeting overweight and obesity. The drug has also received U.S. Food and Drug Administration (FDA) approval to initiate clinical studies, and the first U.S. patient has already been enrolled.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48348#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48348"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48348#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1504.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1504.webp","width":1080,"height":608,"caption":"BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48348#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BrightGene Secures NMPA Nod for BGM1812 Obesity Trial, FDA Grants Trial Clearance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1504.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48348"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48348\/revisions"}],"predecessor-version":[{"id":48357,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48348\/revisions\/48357"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48355"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}